#1 Clinical Trials Search in Europe

Sonidegib

Sonidegib, also known as LDE225 or Odomzo, is an oral medication being studied in various clinical trials for its potential in treating different types of cancer. This article explores the ongoing research into Sonidegib’s effectiveness, safety, and applications across multiple cancer types, including basal cell carcinoma, pancreatic cancer, and other advanced solid tumors.

Table of Contents

What is Sonidegib?

Sonidegib is a medication used in the treatment of certain types of cancer. It is also known by several other names, including:

  • Odomzo
  • LDE225
  • Erismodegib
These alternative names may be used interchangeably in medical literature or by your healthcare provider.[1][2]

What Conditions Does Sonidegib Treat?

Sonidegib is primarily used to treat a type of skin cancer called basal cell carcinoma (BCC). Specifically, it is used for:

  • Locally advanced basal cell carcinoma (laBCC): This is a form of BCC that has grown deeper into nearby tissues but hasn’t spread to other parts of the body.
  • Metastatic basal cell carcinoma (mBCC): This is when the cancer has spread to other parts of the body.
  • Basal cell nevus syndrome (BCNS): Also known as Gorlin syndrome, this is a genetic condition that predisposes individuals to develop multiple BCCs.
Sonidegib is typically used when the cancer cannot be treated with surgery or radiation therapy.[1][3]

How Does Sonidegib Work?

Sonidegib belongs to a class of drugs called Hedgehog pathway inhibitors. The Hedgehog pathway is a complex system of proteins that play a crucial role in cell growth and division. In many types of cancer, including BCC, this pathway becomes overactive, leading to uncontrolled cell growth.

Sonidegib works by blocking a specific protein in this pathway called Smoothened (SMO). By inhibiting SMO, Sonidegib helps to slow down or stop the growth of cancer cells.[1][2]

How is Sonidegib Administered?

Sonidegib is typically taken as an oral medication. The standard dose is usually 200 mg taken once daily. However, the exact dosing schedule can vary depending on the specific treatment plan and the patient’s response to the medication. Some key points about Sonidegib administration include:

  • It is usually taken on an empty stomach, at least 1 hour before or 2 hours after a meal.
  • The capsules should be swallowed whole and not crushed or opened.
  • Dose modifications may be made by your healthcare provider based on how well you tolerate the medication.
Always follow your doctor’s instructions regarding dosage and administration.[1][2]

Current Clinical Trials

Several clinical trials are currently underway to further study the effectiveness of Sonidegib and explore new potential uses:

  • A study is investigating a tailored dosing schedule for patients who have achieved a complete response to Sonidegib. This involves alternating periods of taking the medication and pausing treatment.[2]
  • Another trial is comparing the effectiveness of Sonidegib to another similar drug called Vismodegib in treating various forms of BCC.[3]
  • Researchers are also exploring the potential of combining Sonidegib with other cancer treatments, such as immunotherapy drugs like Pembrolizumab, for treating various advanced solid tumors.[4]

Potential Side Effects

Like all medications, Sonidegib can cause side effects. Some of the most common side effects include:

  • Muscle spasms or pain
  • Hair loss
  • Taste changes
  • Fatigue
  • Nausea
  • Diarrhea or constipation
  • Loss of appetite
Your healthcare provider will monitor you closely for these and other potential side effects. It’s important to report any new or worsening symptoms to your doctor.[1][2]

Future Research and Combinations

Ongoing research is exploring new ways to use Sonidegib, either alone or in combination with other treatments:

  • A study is investigating the combination of Sonidegib with chemotherapy drugs (gemcitabine and nab-paclitaxel) for treating pancreatic cancer.[5]
  • Another trial is looking at combining Sonidegib with two other drugs (sorafenib and irinotecan) for treating liver cancer (hepatocellular carcinoma).[6]
  • Researchers are also studying the potential of Sonidegib in treating certain types of breast cancer.[7]
These studies aim to expand our understanding of how Sonidegib can be used to treat various types of cancer more effectively.

Aspect Details
Drug Name Sonidegib (also known as LDE225, Odomzo)
Drug Class Hedgehog pathway inhibitor
Administration Oral, typically once daily
Dosages Studied 200 mg, 400 mg, 600 mg, 800 mg
Cancer Types Basal cell carcinoma, pancreatic adenocarcinoma, advanced solid tumors
Combination Therapies Gemcitabine, nab-paclitaxel, pembrolizumab
Key Outcomes Measured Safety, tolerability, response rate, progression-free survival, overall survival
Trial Phases Phase 1, Phase 2
Notable Side Effects Muscle spasms, hair loss, taste changes, fatigue (varies by study)
Treatment Duration Varies by study, ranging from several months to 3 years

FAQ

  • What is Sonidegib and how does it work? Sonidegib is an oral medication that works as a Hedgehog pathway inhibitor. It targets and blocks a specific protein involved in cancer cell growth, potentially stopping or slowing down tumor progression.
  • What types of cancer are being studied with Sonidegib? Clinical trials are investigating Sonidegib for various cancers, including locally advanced basal cell carcinoma, pancreatic adenocarcinoma, and other advanced solid tumors such as lung cancer and head and neck cancer.
  • How is Sonidegib administered in clinical trials? In most trials, Sonidegib is taken orally once daily. The dosage may vary depending on the specific study, ranging from 200 mg to 800 mg per day. Some trials combine Sonidegib with other cancer treatments.
  • What are the potential side effects of Sonidegib? While side effects can vary, common ones may include muscle spasms, hair loss, taste changes, and fatigue. Clinical trials closely monitor patients for adverse events and adjust treatment as necessary.
  • How long do patients typically receive Sonidegib in clinical trials? The duration of treatment varies by study. Some trials administer Sonidegib for several months, while others may continue treatment for up to 3 years or until disease progression or unacceptable side effects occur.

Ongoing Clinical Trials on Sonidegib

  • Study of Sonidegib for Patients with Nevoid Basal Cell Carcinoma Syndrome and Sporadic Basal Cell Carcinoma

    Recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study on Personalized Treatment for Post-Pubertal Patients with Newly Diagnosed Medulloblastoma Using Sonidegib, Cisplatin, Lomustine, and Vincristine

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Sonidegib for Patients with Locally Advanced Basal Cell Carcinoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Neoadjuvant therapy: Treatment given before the main treatment, usually to shrink a tumor before surgery.
  • Hedgehog inhibitor: A type of drug that blocks the Hedgehog signaling pathway, which is involved in cell growth and division. Sonidegib is an example of a Hedgehog inhibitor.
  • Basal cell carcinoma (BCC): A type of skin cancer that begins in the basal cells, which produce new skin cells as old ones die off.
  • Locally advanced BCC (laBCC): Basal cell carcinoma that has grown into surrounding tissues but has not spread to other parts of the body.
  • Metastatic BCC (mBCC): Basal cell carcinoma that has spread to other parts of the body beyond its original location.
  • Pancreatic adenocarcinoma: The most common type of pancreatic cancer, which starts in the cells that line the ducts of the pancreas.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Response rate: The percentage of patients whose cancer shrinks or disappears after treatment.
  • Adverse events: Undesired harmful effects that occur during treatment, also known as side effects.

References

  1. https://clinicaltrials.gov/study/NCT04066504
  2. https://clinicaltrials.gov/study/NCT04806646
  3. https://clinicaltrials.gov/study/NCT05463757
  4. https://clinicaltrials.gov/study/NCT04007744
  5. https://clinicaltrials.gov/study/NCT01431794
  6. https://clinicaltrials.gov/study/NCT05669339
  7. https://clinicaltrials.gov/study/NCT01757327